FT011 is primarily investigated for its potential therapeutic applications in treating fibrotic diseases. It has shown promise in preclinical studies for reducing fibrosis in organs such as the kidneys, lungs, and liver by targeting specific pathways involved in fibrotic tissue formation. Researchers are exploring its efficacy in conditions like chronic kidney disease, idiopathic pulmonary fibrosis, and non-alcoholic steatohepatitis (NASH). Its mechanism of action involves inhibiting key proteins or signaling molecules that drive fibrosis, potentially offering a novel approach to managing these progressive and often debilitating conditions. Clinical trials are ongoing to evaluate its safety and effectiveness in human patients.